1. Home
  2. RNA vs LBTYA Comparison

RNA vs LBTYA Comparison

Compare RNA & LBTYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RNA
  • LBTYA
  • Stock Information
  • Founded
  • RNA 2012
  • LBTYA 2004
  • Country
  • RNA United States
  • LBTYA Bermuda
  • Employees
  • RNA N/A
  • LBTYA N/A
  • Industry
  • RNA Biotechnology: Pharmaceutical Preparations
  • LBTYA Cable & Other Pay Television Services
  • Sector
  • RNA Health Care
  • LBTYA Telecommunications
  • Exchange
  • RNA Nasdaq
  • LBTYA Nasdaq
  • Market Cap
  • RNA 4.0B
  • LBTYA 4.1B
  • IPO Year
  • RNA 2020
  • LBTYA N/A
  • Fundamental
  • Price
  • RNA $41.81
  • LBTYA $11.94
  • Analyst Decision
  • RNA Strong Buy
  • LBTYA Buy
  • Analyst Count
  • RNA 16
  • LBTYA 5
  • Target Price
  • RNA $69.81
  • LBTYA $14.96
  • AVG Volume (30 Days)
  • RNA 3.7M
  • LBTYA 1.6M
  • Earning Date
  • RNA 11-06-2025
  • LBTYA 10-30-2025
  • Dividend Yield
  • RNA N/A
  • LBTYA N/A
  • EPS Growth
  • RNA N/A
  • LBTYA N/A
  • EPS
  • RNA N/A
  • LBTYA N/A
  • Revenue
  • RNA $10,729,000.00
  • LBTYA $4,633,000,000.00
  • Revenue This Year
  • RNA N/A
  • LBTYA $10.21
  • Revenue Next Year
  • RNA $109.60
  • LBTYA $1.04
  • P/E Ratio
  • RNA N/A
  • LBTYA N/A
  • Revenue Growth
  • RNA 1.23
  • LBTYA 81.79
  • 52 Week Low
  • RNA $21.51
  • LBTYA $9.03
  • 52 Week High
  • RNA $56.00
  • LBTYA $21.56
  • Technical
  • Relative Strength Index (RSI)
  • RNA 45.80
  • LBTYA 63.13
  • Support Level
  • RNA $39.83
  • LBTYA $11.73
  • Resistance Level
  • RNA $42.42
  • LBTYA $12.01
  • Average True Range (ATR)
  • RNA 2.92
  • LBTYA 0.27
  • MACD
  • RNA -1.12
  • LBTYA -0.04
  • Stochastic Oscillator
  • RNA 38.92
  • LBTYA 82.14

About RNA Avidity Biosciences Inc.

Avidity Biosciences Inc is a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates, or AOCs. Company's pipeline currently has three programs in potentially registrational clinical trials: DM1, FSHD, and DMD. The segments includes following: Del-zota for DMD44, Del-desiran for DM1, Del-brax for FSHD.

About LBTYA Liberty Global Ltd.

Liberty Global is a holding company with interests in European telecom companies in the UK, the Netherlands, Belgium, Ireland, and Slovakia. Liberty owns the main cable network in each of these geographies and has pursued a strategy since 2016 to merge or partner with mobile network operators to be able to offer converged services. Liberty also owns minority stakes in other media, entertainment, and cloud companies.

Share on Social Networks: